Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.8% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTXGet Free Report)’s share price dropped 5.8% on Friday . The stock traded as low as $33.86 and last traded at $33.7910. Approximately 113,707 shares were traded during trading, an increase of 29% from the average session volume of 88,063 shares. The stock had previously closed at $35.88.

Analysts Set New Price Targets

NBTX has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Leerink Partners raised their price target on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. Finally, Guggenheim began coverage on Nanobiotix in a report on Tuesday. They issued a “buy” rating and a $64.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Read Our Latest Stock Report on Nanobiotix

Nanobiotix Price Performance

The business’s 50 day moving average is $39.36 and its 200 day moving average is $37.35.

About Nanobiotix

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.

Further Reading

Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.